NCT06639360 Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
| NCT ID | NCT06639360 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Ischemic Stroke, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-02 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-08-02 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.
Eligibility Criteria
Inclusion Criteria: 1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old. 2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery. 3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy. 4. Pre-stroke mRS score is ≤1. 5. NIHSS score before thrombectomy is between 6 and 25. 6. With vascular recanalization of mTICI \> 2b/3. 7. Informed consent form signed. Exclusion Criteria: 1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.; 2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys; 3. Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention; 4. Head CT/MRI suggests acute cerebral infarction in both sides; 5. Patients who are pregnant or breastfeeding; 6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up; 7. Patients with other severe diseases resulting in an expected survival of less than 90 days; 8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition; 9. Patients who cannot cooperate with informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06639360 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Ischemic Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06639360 currently recruiting?
Yes, NCT06639360 is actively recruiting participants. Contact the research team at zhaojing0110@126.com for enrollment information.
Where is the NCT06639360 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06639360 clinical trial?
NCT06639360 is sponsored by Xijing Hospital. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.